Study About Drug Resistance of Mycobacterium Tuberculosis

NCT ID: NCT07169149

Last Updated: 2025-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-31

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is fundamental. Identifying the pattern of drug resistance will ensure that the most effective therapy can be selected. The aim of this study is to assess the prevalence and patterns of drug resistance of mycobacterium tuberculosis and to detect the possible risk factors associated with resistant cases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary and Extra- Pulmonary Tuberculosis (TB)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* geneXpert positive patients in pulmonary and extrapulmonary cases

Exclusion Criteria

* age below 12 years
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Omnia Abdelazim Mohamed

chest specialist

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag University

Sohag, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Omnia Abdelazeem Zahran

Role: CONTACT

+2 01113328989

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Omnia abdelazeem Zahran, specialist

Role: primary

+2 01113328989

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-25-8---3MD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PanACEA - STEP2C -01
NCT05807399 RECRUITING PHASE2